Drug · DIN 02533928
RISPERIDONE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 28, 2026; first marketed November 9, 2023.
- Drug Identification Number (DIN)
- 02533928
- Company (DIN owner)
- Sivem Pharmaceuticals UlcSaint-Laurent, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Risperidone N05AX08
- Class
- Human
- Record last updated
- October 2, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RISPERIDONE | 0.5 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- September 28, 2023: NOC 38372Abbreviated New Drug Submission (ANDS) · Administrative: Licensing Agreement between two manufacturers
- December 21, 2022: NOC 29755Abbreviated New Drug Submission (ANDS) · Administrative: Licensing Agreement Between Two Companies
Other DINs named RISPERIDONE
- DIN 02356880 · Marketed
- DIN 02356899 · Marketed
- DIN 02356902 · Marketed
- DIN 02356910 · Marketed
- DIN 02356929 · Marketed
- DIN 02356937 · Marketed
- DIN 02533804 · Marketed
- DIN 02533936 · Marketed
- DIN 02533944 · Marketed
- DIN 02533952 · Marketed
- DIN 02533960 · Marketed
- DIN 02303485 · Cancelled Post Market
- DIN 02303493 · Cancelled Post Market
- DIN 02303507 · Cancelled Post Market
- DIN 02303515 · Cancelled Post Market
- DIN 02303523 · Cancelled Post Market
- DIN 02303531 · Cancelled Post Market
- DIN 02343711 · Cancelled Pre Market
- DIN 02343738 · Cancelled Pre Market
- DIN 02343746 · Cancelled Pre Market